Versatile targeting system for lentiviral vectors involving biotinylated targeting molecules.

Publisher: Academic Press Country of Publication: United States NLM ID: 0110674 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-0341 (Electronic) Linking ISSN: 00426822 NLM ISO Abbreviation: Virology Subsets: MEDLINE

Original Publication: New York, Academic Press.

Lentivirus/*physiology; Biotin/metabolism ; Biotinylation ; Gene Expression Regulation, Viral ; Gene Transfer Techniques ; Genetic Vectors ; Transduction, Genetic ; Viral Envelope Proteins/genetics ; Viral Envelope Proteins/metabolism

Conjugating certain types of lentiviral vectors with targeting ligands can redirect the vectors to specifically transduce desired cell types. However, extensive genetic and/or biochemical manipulations are required for conjugation, which hinders applications for targeting lentiviral vectors for broader research fields. We developed envelope proteins fused with biotin-binding molecules to conjugate the pseudotyped vectors with biotinylated targeting molecules by simply mixing them. The envelope proteins fused with the monomeric, but not tetrameric, biotin-binding molecules can pseudotype lentiviral vectors and be conjugated with biotinylated targeting ligands. The conjugation is stable enough to redirect lentiviral transduction in the presence of serum, indicating their potential in in vivo . When a signaling molecule is conjugated with the vector, the conjugation facilitates transduction and signaling in a receptor-specific manner. This simple method of ligand conjugation and ease of obtaining various types of biotinylated ligands will make targeted lentiviral transduction easily applicable to broad fields of research.
(Copyright © 2018 Elsevier Inc. All rights reserved.)

J Gene Med. 2008 Mar;10(3):242-8. (PMID: 18074400)
Cell Cycle. 2005 Jul;4(7):854-6. (PMID: 15970695)
PLoS Pathog. 2016 Jun 09;12(6):e1005641. (PMID: 27281338)
Nature. 2010 Sep 16;467(7313):318-22. (PMID: 20844535)
J Gene Med. 2009 Aug;11(8):655-63. (PMID: 19455593)
Nat Biotechnol. 2005 Feb;23(2):209-14. (PMID: 15685166)
Curr Opin Virol. 2011 Jul;1(1):13-8. (PMID: 21804908)
Proteins. 2013 Sep;81(9):1621-33. (PMID: 23670729)
Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11382-8. (PMID: 8876144)
J Gene Med. 2009 Mar;11(3):185-96. (PMID: 19152374)
Structure. 1994 Dec 15;2(12):1259-70. (PMID: 7704534)
Mol Cancer. 2012 Oct 22;11:81. (PMID: 23088623)
Virology. 2004 Dec 5;330(1):24-33. (PMID: 15527831)
Structure. 2006 Jan;14(1):63-73. (PMID: 16407066)
J Virol. 2013 Jun;87(11):6246-56. (PMID: 23536664)
Nat Med. 2006 May;12(5):585-91. (PMID: 16633348)
Science. 2016 Sep 9;353(6304):1101-2. (PMID: 27609877)
Mol Biotechnol. 2016 Nov;58(11):738-747. (PMID: 27647452)
Nature. 2010 Dec 2;468(7324):705-8. (PMID: 21124457)
J Virol. 2001 Sep;75(17):8016-20. (PMID: 11483746)
Sci Rep. 2018 Jul 20;8(1):10990. (PMID: 30030466)
Nat Med. 2005 Mar;11(3):346-52. (PMID: 15711560)
Methods Enzymol. 1990;184:49-51. (PMID: 2201883)
J Virol. 2010 Jul;84(14):6923-34. (PMID: 20484510)
Blood. 1998 Mar 1;91(5):1802-9. (PMID: 9473249)
Virology. 2006 Nov 10;355(1):71-81. (PMID: 16905172)
Nat Biotechnol. 1997 Aug;15(8):763-7. (PMID: 9255791)
Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7570-4. (PMID: 7638232)
J Virol. 1999 Aug;73(8):6299-306. (PMID: 10400721)
Cell Mol Life Sci. 2006 Dec;63(24):2992-3017. (PMID: 17086379)
Angew Chem Int Ed Engl. 2016 Mar 1;55(10):3393-7. (PMID: 26833545)
Cell Host Microbe. 2013 Aug 14;14(2):136-47. (PMID: 23954153)
J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):152-61. (PMID: 19593160)
Science. 1996 Apr 12;272(5259):263-7. (PMID: 8602510)
Gene Ther. 2009 Jul;16(7):894-904. (PMID: 19440224)
Breast Cancer Res Treat. 2011 Jan;125(1):89-97. (PMID: 20232140)
Science. 1994 Nov 25;266(5189):1373-6. (PMID: 7973726)
Mol Cancer Res. 2013 Oct;11(10):1141-58. (PMID: 23928056)
J Virol. 2014 Apr;88(8):4275-90. (PMID: 24478428)
J Virol. 2000 Sep;74(17):7772-80. (PMID: 10933683)
Hum Gene Ther. 2005 Feb;16(2):223-34. (PMID: 15761262)
J Virol. 1993 Jun;67(6):3363-74. (PMID: 7684466)
Mol Ther. 2008 Aug;16(8):1427-36. (PMID: 18578012)
Cancer Gene Ther. 2009 Nov;16(11):820-31. (PMID: 19373278)
Nature. 2018 Jun;558(7709):307-312. (PMID: 29849141)
J Virol. 2009 Dec;83(24):13026-31. (PMID: 19793825)
Cell. 1990 Apr 20;61(2):213-22. (PMID: 2331748)
Nucl Med Biol. 2014 Jan;41(1):77-83. (PMID: 24267054)
Curr Top Microbiol Immunol. 2003;281:137-78. (PMID: 12932077)
J Clin Invest. 2010 Jan;120(1):379-89. (PMID: 20038801)
Mol Ther. 2007 Nov;15(11):1973-81. (PMID: 17653099)
Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11479-84. (PMID: 16864770)
J Gene Med. 2010 Dec;12(12):945-55. (PMID: 21104972)
Cell. 2001 Apr 6;105(1):127-136. (PMID: 11301008)
Cell Host Microbe. 2011 Apr 21;9(4):286-98. (PMID: 21501828)
J Virol. 1998 Apr;72(4):3161-8. (PMID: 9525642)
Biochem J. 2007 Aug 1;405(3):397-405. (PMID: 17447892)
PLoS One. 2012;7(4):e34778. (PMID: 22536330)
Nature. 2006 Jun 15;441(7095):847-52. (PMID: 16728975)
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):4005-10. (PMID: 10097153)
J Gene Med. 2009 Jul;11(7):549-58. (PMID: 19434609)
Nature. 1981 Jan 29;289(5796):366-73. (PMID: 7464906)
Lancet. 2016 Jul 30;388(10043):476-87. (PMID: 27289174)
Nat Med. 2016 Feb;22(2):154-62. (PMID: 26779814)
Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13144-9. (PMID: 16924110)
Sci Immunol. 2017 Jul 21;2(13):null. (PMID: 28733470)
Mol Ther. 2011 Apr;19(4):686-93. (PMID: 21224833)
MBio. 2017 Dec 12;8(6):. (PMID: 29233896)

DP5 OD019815 United States OD NIH HHS; R01 AI108400 United States AI NIAID NIH HHS; R21 AI095004 United States AI NIAID NIH HHS

Keywords: Biotin; Lentiviral vectors; Rhizavidin; Signaling; Streptavidin; Targeting

0 (Viral Envelope Proteins)
6SO6U10H04 (Biotin)

Date Created: 20181006 Date Completed: 20190107 Latest Revision: 20191201

20240829

PMC6269213

10.1016/j.virol.2018.09.017

30290312